Public | |
Traded as | : BAX S&P 500 Component |
Industry | Medical equipment |
Founded | 1931 |
Headquarters | Deerfield, Illinois, U.S. |
Key people
|
José E. Almeida, (Chairman & CEO) |
Products | Medical supplies to treat hemophilia, kidney disease and provide intravenous therapy |
Revenue | US$16.3B (FY 2014) |
US$2.012B (FY 2014) | |
Total assets | US$25.9B (FY 2014) |
Total equity | US$8.5B (FY 2014) |
Number of employees
|
61,500 |
Website | https://www.baxter.com |
José E. Almeida, (Chairman & CEO)
Baxter International Inc. is an American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had 2013 sales of $16.3 billion, across two businesses: BioScience and Medical Products. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine, and vaccines. Baxter's Medical Products business produces intravenous products and other products used in the delivery of fluids and drugs to patients; inhalational anaesthetics; contract manufacturing services; and products to treat end-stage renal disease, or irreversible kidney failure, including products for peritoneal dialysis and hemodialysis.
Baxter International was founded in 1931 by Donald Baxter, a medical doctor, as a manufacturer and distributor of intravenous therapy solutions. Baxter's interest was bought out in 1935 by Ralph Falk, who established a research and development function. In 1939 the company developed a vacuum-type collection container, extending the shelf life of blood from hours to weeks. In 1954, the company expanded operations outside of the United States by opening an office in Belgium. In 1956 Baxter International introduced the first functioning artificial kidney, and in 1971 became a member of the Fortune 500.